TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06447025: An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

Sponsor: Larimar Therapeutics, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 85 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,460,800

Rescue Site Savings

+$962,800

Unlock Full NCT06447025 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06447025 Rescue Dossier →